JP2017501725A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017501725A5 JP2017501725A5 JP2016542697A JP2016542697A JP2017501725A5 JP 2017501725 A5 JP2017501725 A5 JP 2017501725A5 JP 2016542697 A JP2016542697 A JP 2016542697A JP 2016542697 A JP2016542697 A JP 2016542697A JP 2017501725 A5 JP2017501725 A5 JP 2017501725A5
- Authority
- JP
- Japan
- Prior art keywords
- fcrn antagonist
- region
- pharmaceutical composition
- fcrn
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361920547P | 2013-12-24 | 2013-12-24 | |
| US61/920,547 | 2013-12-24 | ||
| PCT/US2014/072087 WO2015100299A1 (en) | 2013-12-24 | 2014-12-23 | Fcrn antagonists and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019002272A Division JP2019076103A (ja) | 2013-12-24 | 2019-01-10 | ＦｃＲｎアンタゴニスト及び使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017501725A JP2017501725A (ja) | 2017-01-19 |
| JP2017501725A5 true JP2017501725A5 (enExample) | 2017-12-14 |
| JP6554473B2 JP6554473B2 (ja) | 2019-07-31 |
Family
ID=52347464
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016542697A Active JP6554473B2 (ja) | 2013-12-24 | 2014-12-23 | ＦｃＲｎアンタゴニスト及び使用方法 |
| JP2019002272A Pending JP2019076103A (ja) | 2013-12-24 | 2019-01-10 | ＦｃＲｎアンタゴニスト及び使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019002272A Pending JP2019076103A (ja) | 2013-12-24 | 2019-01-10 | ＦｃＲｎアンタゴニスト及び使用方法 |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US10316073B2 (enExample) |
| EP (2) | EP3087095B1 (enExample) |
| JP (2) | JP6554473B2 (enExample) |
| KR (3) | KR102452173B1 (enExample) |
| CN (2) | CN106103476B (enExample) |
| AU (1) | AU2014369999B2 (enExample) |
| BR (1) | BR112016014810B1 (enExample) |
| CA (1) | CA2934644C (enExample) |
| DK (1) | DK3087095T3 (enExample) |
| EA (1) | EA035324B1 (enExample) |
| ES (1) | ES2742682T3 (enExample) |
| FI (1) | FIC20230003I1 (enExample) |
| FR (1) | FR23C1004I2 (enExample) |
| HU (2) | HUE046822T2 (enExample) |
| IL (1) | IL246223B (enExample) |
| LT (2) | LT3087095T (enExample) |
| LU (1) | LUC00284I2 (enExample) |
| MX (1) | MX368804B (enExample) |
| NL (1) | NL301203I2 (enExample) |
| NO (1) | NO2022049I1 (enExample) |
| NZ (1) | NZ722055A (enExample) |
| PL (1) | PL3087095T3 (enExample) |
| PT (1) | PT3087095T (enExample) |
| SG (2) | SG10202009832XA (enExample) |
| WO (1) | WO2015100299A1 (enExample) |
| ZA (2) | ZA201604464B (enExample) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2934644C (en) | 2013-12-24 | 2023-11-21 | Argen-X N.V. | Fcrn antagonists and methods of use |
| KR102720769B1 (ko) * | 2015-03-09 | 2024-10-22 | 아르제넥스 비브이 | FcRn 길항제를 사용하여 Fc-함유된 제제의 혈청 수준을 감소시키는 방법 |
| FR3038517B1 (fr) * | 2015-07-06 | 2020-02-28 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Utilisation de fragments fc modifies en immunotherapie |
| CN106957364B (zh) * | 2016-01-11 | 2021-03-16 | 上海交通大学 | 一种单克隆抗体FnAb12及其应用 |
| CN106957365B (zh) * | 2016-01-11 | 2021-03-16 | 上海交通大学 | 一种单克隆抗体FnAb8及其应用 |
| EP3257866A1 (en) * | 2016-06-17 | 2017-12-20 | Academisch Medisch Centrum | Modified anti-tnf antibody and use thereof in the treatment of ibd |
| EP3481864A1 (en) | 2016-07-08 | 2019-05-15 | Staten Biotechnology B.V. | Anti-apoc3 antibodies and methods of use thereof |
| GB201618424D0 (en) * | 2016-11-01 | 2016-12-14 | Argenix Bvba | Treatment of antibody mediated disease |
| AU2017366674B2 (en) | 2016-12-02 | 2025-01-02 | The Texas A&M University System | Fusion proteins for selectively depleting antigen-specific antibodies |
| CA3059133A1 (en) | 2017-04-21 | 2018-10-25 | Staten Biotechnology B.V. | Anti-apoc3 antibodies and methods of use thereof |
| CA3080103A1 (en) | 2017-10-31 | 2019-05-09 | Staten Biotechnology B.V. | Anti-apoc3 antibodies and methods of use thereof |
| MX2020005981A (es) | 2017-12-08 | 2020-08-24 | Argenx Bvba | Uso de antagonistas del fcrn para el tratamiento de la miastenia gravis generalizada. |
| EP3802590A2 (en) | 2018-06-08 | 2021-04-14 | Argenx BVBA | Compositions and methods for treating immune thrombocytopenia |
| UA130214C2 (uk) * | 2018-07-20 | 2025-12-24 | Момента Фармасьютикалз, Інк. | Фармацевтична композиція антитіл проти fcrn |
| WO2020054979A1 (ko) * | 2018-09-12 | 2020-03-19 | 아주대학교산학협력단 | Cd83 억제제를 유효성분으로 포함하는 베체트병의 예방 또는 치료용 조성물 |
| GB2589049C (en) * | 2019-04-11 | 2024-02-21 | argenx BV | Anti-IgE antibodies |
| BR112021022682A2 (pt) | 2019-05-14 | 2022-02-22 | Provention Bio Inc | Métodos e composições para prevenir diabetes do tipo 1 |
| EP3980063A1 (en) * | 2019-06-07 | 2022-04-13 | Argenx BVBA | Pharmaceutical formulations of fcrn inhibitors suitable for subcutaneous administration |
| KR20220148804A (ko) | 2020-01-08 | 2022-11-07 | 아르젠엑스 비브이 | 천포창 장애의 치료 방법 |
| CN114341184B (zh) * | 2020-02-10 | 2023-04-04 | 北京拓界生物医药科技有限公司 | 抗FcRn抗体、其抗原结合片段及其医药用途 |
| CN113769058B (zh) * | 2020-06-10 | 2024-09-06 | 上海宝济药业股份有限公司 | 一种药物组合及其应用 |
| US12006366B2 (en) | 2020-06-11 | 2024-06-11 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| WO2022251253A1 (en) | 2021-05-24 | 2022-12-01 | Provention Bio, Inc. | Methods for treating type 1 diabetes |
| US20240309065A1 (en) | 2021-06-23 | 2024-09-19 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Short apoc-ii mimetic peptides and methods of use |
| MX2024006275A (es) | 2022-01-18 | 2024-06-11 | argenx BV | Anticuerpos para galectina-10. |
| TW202337895A (zh) | 2022-02-21 | 2023-10-01 | 比利時商阿根思公司 | 使用ｆｃｒｎ拮抗劑治療肌炎之方法 |
| CN119013290A (zh) | 2022-04-13 | 2024-11-22 | Ose免疫疗法公司 | 用于选择性清除抗体的新型分子 |
| EP4519300A1 (en) | 2022-05-05 | 2025-03-12 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Short apolipoprotein e mimetic peptides and methods of use |
| CA3258004A1 (en) | 2022-06-15 | 2023-12-21 | argenx BV | FCRN/HSA BONDING MOLECULES AND METHODS OF USE |
| CN115645537A (zh) * | 2022-10-25 | 2023-01-31 | 成都臻拓医药科技有限公司 | FcRn抑制剂在制备抑制自身免疫性疾病复发的药物中的用途 |
| KR20250109198A (ko) * | 2022-11-14 | 2025-07-16 | 아르젠엑스 비브이 | Fcrn 길항제 분자 및 이의 사용 방법 |
| WO2024163894A1 (en) | 2023-02-04 | 2024-08-08 | Momenta Pharmaceuticals, Inc. | Compositions and methods for treating hemolytic disease of the fetus and newborn |
| AR131869A1 (es) | 2023-02-17 | 2025-05-07 | Ablynx Nv | POLIPÉPTIDOS QUE SE UNEN AL RECEPTOR DE Fc NEONATAL |
| AU2024242538A1 (en) * | 2023-03-24 | 2025-10-30 | Paragon Therapeutics, Inc. | Fc fragments that bind fcrn and methods of use |
| CN121443644A (zh) | 2023-07-05 | 2026-01-30 | 阿布林克斯有限公司 | 用于治疗IgG相关疾病和障碍的改善的FcRn拮抗剂 |
| CN121843716A (zh) | 2023-07-16 | 2026-04-10 | 阿根思有限公司 | 用于治疗慢性炎性脱髓鞘性多发性神经病的方法 |
| TW202527982A (zh) | 2023-09-11 | 2025-07-16 | 美商默門塔醫藥公司 | Fcrn抗體之醫藥組成物 |
| WO2025099576A1 (en) | 2023-11-06 | 2025-05-15 | Momenta Pharmaceuticals, Inc. | Compositions and methods for treating rheumatoid arthritis |
| GB202319605D0 (en) | 2023-12-20 | 2024-01-31 | argenx BV | Monovalent binding molecules and methods of use |
| WO2025163617A1 (en) | 2024-02-04 | 2025-08-07 | Momenta Pharmaceuticals, Inc. | Compositions and methods for treating sjögren's disease |
| WO2025186787A1 (en) | 2024-03-08 | 2025-09-12 | Momenta Pharmaceuticals, Inc. | Compositions and methods for treating fetal and neonatal alloimmune thrombocytopenia |
| WO2025229206A1 (en) | 2024-05-03 | 2025-11-06 | argenx BV | Monovalent anti-iga binding molecules and methods of use |
| WO2025233685A1 (en) | 2024-05-10 | 2025-11-13 | argenx BV | Intravenous fcrn antagonist formulations and methods of use thereof |
| WO2025233684A1 (en) | 2024-05-10 | 2025-11-13 | argenx BV | Subcutaneous formulations, pre-filled syringes and methods of use thereof |
| WO2026083290A1 (en) | 2024-10-16 | 2026-04-23 | Momenta Pharmaceuticals, Inc. | Compositions and methods for treating sjögren's disease |
| CN119490588B (zh) * | 2024-10-17 | 2026-03-06 | 广州康盛生物科技股份有限公司 | 一种抗人FcRn的VHH抗体及其应用 |
Family Cites Families (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62153300A (ja) * | 1985-12-26 | 1987-07-08 | Teijin Ltd | ヒト免疫グロブリンＧＦｃ領域蛋白質およびその製造方法 |
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| US5326856A (en) | 1992-04-09 | 1994-07-05 | Cytogen Corporation | Bifunctional isothiocyanate derived thiocarbonyls as ligands for metal binding |
| CA2118508A1 (en) | 1992-04-24 | 1993-11-11 | Elizabeth S. Ward | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| JPH08511420A (ja) | 1993-06-16 | 1996-12-03 | セルテック・セラピューテイクス・リミテッド | 抗 体 |
| ATE331438T1 (de) | 1995-01-17 | 2006-07-15 | Brigham & Womens Hospital | Rezeptorspezifischer transepithelealer transport von immunogenen |
| US6030613A (en) | 1995-01-17 | 2000-02-29 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| ATE279947T1 (de) | 1996-03-18 | 2004-11-15 | Univ Texas | Immunglobulinähnliche domäne mit erhöhten halbwertszeiten |
| US6128119A (en) | 1997-01-10 | 2000-10-03 | Asahi Kogaku Kogyo Kabushiki Kaisha | Beam shaping optical system |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| KR100940380B1 (ko) | 1999-01-15 | 2010-02-02 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| JP5179689B2 (ja) | 2000-02-11 | 2013-04-10 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗体ベース融合タンパク質の循環系内半減期の増強 |
| US6725230B2 (en) | 2000-07-18 | 2004-04-20 | Aegis Analytical Corporation | System, method and computer program for assembling process data of multi-database origins using a hierarchical display |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| US6992234B2 (en) | 2000-11-06 | 2006-01-31 | The Jackson Laboratory | FcRn-based therapeutics for the treatment of auto-immune disorders |
| CA2467781C (en) | 2000-11-20 | 2014-09-23 | Canadian Blood Services | Use of a monoclonal antibody specific for a red blood cell to inhibit the reticuloendothelial system for the treatment of thrombocytopenia |
| JP4336498B2 (ja) | 2000-12-12 | 2009-09-30 | メディミューン，エルエルシー | 延長した半減期を有する分子ならびにその組成物および用途 |
| NZ581474A (en) | 2001-08-03 | 2011-04-29 | Glycart Biotechnology Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
| US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| JP3945281B2 (ja) | 2002-03-19 | 2007-07-18 | 富士ゼロックス株式会社 | 画像形成装置 |
| JP4524181B2 (ja) | 2002-05-30 | 2010-08-11 | マクロジェニクス，インコーポレーテッド | Ｃｄ１６ａ結合タンパク質および免疫障害治療のための使用 |
| WO2004016750A2 (en) | 2002-08-14 | 2004-02-26 | Macrogenics, Inc. | FcϜRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF |
| WO2004029207A2 (en) | 2002-09-27 | 2004-04-08 | Xencor Inc. | Optimized fc variants and methods for their generation |
| WO2004035752A2 (en) | 2002-10-15 | 2004-04-29 | Protein Design Labs, Inc. | ALTERATION OF FcRn BINDING AFFINITIES OR SERUM HALF-LIVES OF ANTIBODIES BY MUTAGENESIS |
| EP1588166A4 (en) | 2003-01-09 | 2007-06-27 | Macrogenics Inc | VECTOR SYSTEM WITH DOUBLE EXPRESSION FOR EXPRESSING ANTIBODIES IN BACTERIAL AND MAMMAL CELLS |
| EP2368578A1 (en) | 2003-01-09 | 2011-09-28 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| CA2512974A1 (en) | 2003-01-13 | 2004-07-29 | Macrogenics, Inc. | Soluble fc.gamma.r fusion proteins and methods of use thereof |
| US7662928B2 (en) | 2003-08-08 | 2010-02-16 | The Research Foundation Of State University Of New York | Anti-FcRn antibodies for treatment of auto/allo immune conditions |
| GB0324368D0 (en) | 2003-10-17 | 2003-11-19 | Univ Cambridge Tech | Polypeptides including modified constant regions |
| EP1798864A4 (en) | 2004-09-30 | 2013-07-31 | Brother Ind Ltd | WIRELESS LABEL COMMUNICATION DEVICE, WIRELESS LABEL, WIRELESS COMMUNICATION SYSTEM AND METHOD OF WIRELESS COMMUNICATION |
| US20100266530A1 (en) * | 2005-04-29 | 2010-10-21 | The Jackson Laboratory | FcRN ANTIBODIES AND USES THEREOF |
| US8163881B2 (en) * | 2005-05-31 | 2012-04-24 | The Board Of Regents Of The University Of Texas System | Immunoglobulin molecules with improved characteristics |
| TW200745163A (en) | 2006-02-17 | 2007-12-16 | Syntonix Pharmaceuticals Inc | Peptides that block the binding of IgG to FcRn |
| CA2682605A1 (en) | 2007-04-18 | 2008-10-30 | Zymogenetics, Inc. | Single chain fc, methods of making and methods of treatment |
| EP2158318A2 (en) | 2007-05-14 | 2010-03-03 | Biogen Idec MA, Inc. | Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto |
| CN103897063B (zh) * | 2007-06-01 | 2017-04-12 | 马里兰大学巴尔的摩分校 | 免疫球蛋白恒定区Fc受体结合剂 |
| US8108517B2 (en) | 2007-11-27 | 2012-01-31 | Umber Systems | System and method for collecting, reporting and analyzing data on application-level activity and other user information on a mobile data network |
| US20110059091A1 (en) | 2008-02-04 | 2011-03-10 | Xiao-Jia Chang | Inhibitors of oncogenic isoforms and uses thereof |
| US9260525B2 (en) * | 2008-02-04 | 2016-02-16 | Xiao-Jia Chang | Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof |
| TWI593423B (zh) * | 2008-04-25 | 2017-08-01 | 戴埃克斯有限公司 | Ｆｃ受體結合蛋白 |
| US20100048488A1 (en) * | 2008-08-01 | 2010-02-25 | Syntonix Pharmaceuticals, Inc. | Immunomodulatory peptides |
| EP2233500A1 (en) * | 2009-03-20 | 2010-09-29 | LFB Biotechnologies | Optimized Fc variants |
| AU2010303415B2 (en) * | 2009-10-07 | 2015-02-19 | Macrogenics, Inc. | Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use |
| EP3543257A1 (en) * | 2010-07-28 | 2019-09-25 | Gliknik Inc. | Fusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin fc compositions |
| GB201111291D0 (en) | 2011-06-30 | 2011-08-17 | Agco Int Gmbh | Engine control system |
| AU2012328819B2 (en) | 2011-10-26 | 2017-08-03 | Elanco Tiergesundheit Ag | Monoclonal antibodies and methods of use |
| EP2780463A4 (en) | 2011-11-18 | 2015-07-01 | Merck Sharp & Dohme | FC-CONTAINING POLYPEPTIDES WITH INCREASED INFLAMMATORY FEATURES AND INCREASED FCRN BINDING |
| KR102041412B1 (ko) * | 2011-12-30 | 2019-11-11 | 한미사이언스 주식회사 | 면역글로불린 Ｆｃ 단편 유도체 |
| GB201208370D0 (en) | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Antibodies |
| PL2870247T3 (pl) | 2012-07-05 | 2019-10-31 | Hoffmann La Roche | Układ ekspresji i wydzielania |
| GB201302878D0 (en) * | 2013-02-19 | 2013-04-03 | Argen X Bv | Modified igG molecules |
| KR101815265B1 (ko) | 2013-06-20 | 2018-01-04 | 한올바이오파마주식회사 | FcRn 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물 |
| JP6620094B2 (ja) | 2013-11-26 | 2019-12-11 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． | 免疫応答を調節するための組成物および方法 |
| CA2934644C (en) | 2013-12-24 | 2023-11-21 | Argen-X N.V. | Fcrn antagonists and methods of use |
| US10323066B2 (en) | 2014-09-17 | 2019-06-18 | Affibody Ab | Neonatal Fc receptor binding dimer and methods of use |
| SG10202007232WA (en) | 2015-01-30 | 2020-09-29 | Momenta Pharmaceuticals Inc | Fcrn antibodies and methods of use thereof |
| KR102720769B1 (ko) | 2015-03-09 | 2024-10-22 | 아르제넥스 비브이 | FcRn 길항제를 사용하여 Fc-함유된 제제의 혈청 수준을 감소시키는 방법 |
| HK1251483A1 (zh) | 2015-05-12 | 2019-02-01 | Synt免疫公司 | 人源化亲和力成熟的抗fcrn抗体 |
| GB201508180D0 (en) | 2015-05-13 | 2015-06-24 | Ucb Biopharma Sprl | Antibodies |
| WO2017012959A1 (en) | 2015-07-17 | 2017-01-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for inducing immune tolerance by mucosal vaccination with fc-coupled antigens |
| CN106957365B (zh) | 2016-01-11 | 2021-03-16 | 上海交通大学 | 一种单克隆抗体FnAb8及其应用 |
| GB201618424D0 (en) | 2016-11-01 | 2016-12-14 | Argenix Bvba | Treatment of antibody mediated disease |
| MX2020005981A (es) | 2017-12-08 | 2020-08-24 | Argenx Bvba | Uso de antagonistas del fcrn para el tratamiento de la miastenia gravis generalizada. |
| EP3802590A2 (en) | 2018-06-08 | 2021-04-14 | Argenx BVBA | Compositions and methods for treating immune thrombocytopenia |
| JP2022532229A (ja) | 2019-05-17 | 2022-07-13 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 天疱瘡及び類天疱瘡疾患の治療における抗ＦｃＲｎ抗体の使用 |
| EP3980063A1 (en) * | 2019-06-07 | 2022-04-13 | Argenx BVBA | Pharmaceutical formulations of fcrn inhibitors suitable for subcutaneous administration |
-
2014
- 2014-12-23 CA CA2934644A patent/CA2934644C/en active Active
- 2014-12-23 US US14/580,771 patent/US10316073B2/en active Active
- 2014-12-23 BR BR112016014810-0A patent/BR112016014810B1/pt active IP Right Grant
- 2014-12-23 KR KR1020167020339A patent/KR102452173B1/ko active Active
- 2014-12-23 NZ NZ722055A patent/NZ722055A/en unknown
- 2014-12-23 CN CN201480070435.1A patent/CN106103476B/zh active Active
- 2014-12-23 AU AU2014369999A patent/AU2014369999B2/en active Active
- 2014-12-23 PT PT148273725T patent/PT3087095T/pt unknown
- 2014-12-23 EA EA201691304A patent/EA035324B1/ru unknown
- 2014-12-23 KR KR1020247006088A patent/KR20240033084A/ko not_active Ceased
- 2014-12-23 MX MX2016008399A patent/MX368804B/es active IP Right Grant
- 2014-12-23 EP EP14827372.5A patent/EP3087095B1/en active Active
- 2014-12-23 HU HUE14827372A patent/HUE046822T2/hu unknown
- 2014-12-23 PL PL14827372T patent/PL3087095T3/pl unknown
- 2014-12-23 SG SG10202009832XA patent/SG10202009832XA/en unknown
- 2014-12-23 DK DK14827372T patent/DK3087095T3/da active
- 2014-12-23 JP JP2016542697A patent/JP6554473B2/ja active Active
- 2014-12-23 WO PCT/US2014/072087 patent/WO2015100299A1/en not_active Ceased
- 2014-12-23 SG SG11201605203UA patent/SG11201605203UA/en unknown
- 2014-12-23 EP EP19189186.0A patent/EP3626738A1/en active Pending
- 2014-12-23 LT LTEP14827372.5T patent/LT3087095T/lt unknown
- 2014-12-23 ES ES14827372T patent/ES2742682T3/es active Active
- 2014-12-23 KR KR1020227034365A patent/KR20220152546A/ko not_active Ceased
- 2014-12-23 CN CN202010983097.8A patent/CN112142843B/zh active Active
-
2016
- 2016-06-14 IL IL246223A patent/IL246223B/en unknown
- 2016-06-30 ZA ZA2016/04464A patent/ZA201604464B/en unknown
-
2017
- 2017-11-22 US US15/821,104 patent/US11505585B2/en active Active
-
2019
- 2019-01-10 JP JP2019002272A patent/JP2019076103A/ja active Pending
-
2022
- 2022-02-15 US US17/672,346 patent/US20220275035A1/en active Pending
- 2022-11-03 NL NL301203C patent/NL301203I2/nl unknown
- 2022-11-09 LU LU00284C patent/LUC00284I2/fr unknown
- 2022-11-15 LT LTPA2022014C patent/LTC3087095I2/lt unknown
- 2022-11-21 HU HUS2200048C patent/HUS2200048I1/hu unknown
- 2022-11-23 NO NO2022049C patent/NO2022049I1/no unknown
-
2023
- 2023-01-12 FR FR23C1004C patent/FR23C1004I2/fr active Active
- 2023-01-19 FI FIC20230003C patent/FIC20230003I1/fi unknown
-
2024
- 2024-12-23 ZA ZA2024/09972A patent/ZA202409972B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022105084A5 (enExample) | ||
| JP2018509413A5 (enExample) | ||
| US20260001960A1 (en) | Antibodies against signal-regulatory protein alpha and methods of use | |
| CN110121510B (zh) | 程序性细胞死亡(pd-1)的单结构域抗体 | |
| CN110669135B (zh) | 一种双特异性抗体及其用途 | |
| JP2019073512A (ja) | ヘテロ二量体免疫グロブリンの精製 | |
| JP2016527187A5 (enExample) | ||
| JP2014515598A (ja) | 二重特異性三鎖抗体様分子 | |
| JP2011506422A5 (enExample) | ||
| AU2023291783A1 (en) | Fcrn binding molecules and methods of use | |
| JP2025520420A5 (enExample) | ||
| JP7688805B2 (ja) | 二重特異性抗体 | |
| JPWO2020004490A5 (enExample) | ||
| WO2016021621A1 (ja) | 新規抗ヒトＩｇβ抗体 | |
| CN109641953B (zh) | 针对il-17a、il-17f和其他促炎性分子的三特异性抗体 | |
| JP2021075580A5 (enExample) | ||
| WO2019099744A1 (en) | METHODS FOR SELECTIVE EXPANSION OF δ3 γδ T-CELL POPULATIONS AND COMPOSITIONS THEREOF | |
| WO2016031932A1 (ja) | アルカリ洗浄によるＦｃ領域を有するタンパク質の製造方法 | |
| NZ773089B2 (en) | Methods of reducing serum levels of fc-containing agents using fcrn antagonists | |
| NZ773089A (en) | Methods of reducing serum levels of fc-containing agents using fcrn antagonists | |
| CN117157323A (zh) | 新型多特异性抗体 | |
| JP2025508073A5 (enExample) | ||
| RU2814713C2 (ru) | Биспецифическое антитело | |
| CN121627895A (zh) | 抗MerTK抗体及其应用 | |
| RU2023135361A (ru) | Белки, которые связываются с cd80 и/или cd86 и ox40l |